Meros Investment Management LP Raises Holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB)

Meros Investment Management LP increased its position in shares of Mesa Laboratories, Inc. (NASDAQ:MLAB - Free Report) by 21.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 40,263 shares of the medical instruments supplier's stock after buying an additional 7,023 shares during the quarter. Mesa Laboratories comprises approximately 2.4% of Meros Investment Management LP's portfolio, making the stock its 19th largest position. Meros Investment Management LP owned about 0.74% of Mesa Laboratories worth $5,309,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Franklin Resources Inc. grew its stake in shares of Mesa Laboratories by 27.8% in the third quarter. Franklin Resources Inc. now owns 6,444 shares of the medical instruments supplier's stock worth $828,000 after acquiring an additional 1,403 shares in the last quarter. Barclays PLC grew its stake in shares of Mesa Laboratories by 357.4% during the third quarter. Barclays PLC now owns 8,837 shares of the medical instruments supplier's stock worth $1,148,000 after purchasing an additional 6,905 shares in the last quarter. JPMorgan Chase & Co. grew its stake in shares of Mesa Laboratories by 29.3% during the third quarter. JPMorgan Chase & Co. now owns 8,406 shares of the medical instruments supplier's stock worth $1,092,000 after purchasing an additional 1,906 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of Mesa Laboratories by 4.3% during the fourth quarter. Pacer Advisors Inc. now owns 1,755 shares of the medical instruments supplier's stock worth $231,000 after purchasing an additional 73 shares in the last quarter. Finally, Conestoga Capital Advisors LLC grew its stake in shares of Mesa Laboratories by 8.3% during the fourth quarter. Conestoga Capital Advisors LLC now owns 573,037 shares of the medical instruments supplier's stock worth $75,566,000 after purchasing an additional 43,927 shares in the last quarter. Hedge funds and other institutional investors own 90.60% of the company's stock.

Insider Activity

In other news, CEO Gary M. Owens sold 21,000 shares of the company's stock in a transaction dated Wednesday, March 19th. The shares were sold at an average price of $123.91, for a total value of $2,602,110.00. Following the completion of the sale, the chief executive officer now directly owns 43,337 shares of the company's stock, valued at approximately $5,369,887.67. This represents a 32.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.40% of the company's stock.

Mesa Laboratories Stock Up 0.9%

Shares of MLAB stock traded up $1.07 on Friday, reaching $122.42. 35,545 shares of the stock were exchanged, compared to its average volume of 39,849. The company has a current ratio of 0.71, a quick ratio of 0.53 and a debt-to-equity ratio of 0.61. The business's 50 day moving average price is $118.33 and its 200 day moving average price is $126.74. The company has a market capitalization of $665.23 million, a price-to-earnings ratio of -2.65 and a beta of 0.97. Mesa Laboratories, Inc. has a twelve month low of $83.68 and a twelve month high of $155.12.

Mesa Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, June 16th. Shareholders of record on Friday, May 30th will be paid a $0.16 dividend. The ex-dividend date is Friday, May 30th. This represents a $0.64 annualized dividend and a yield of 0.52%. Mesa Laboratories's dividend payout ratio is presently -1.38%.

About Mesa Laboratories

Mesa Laboratories, Inc develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries.